Ortho-McNeil launches Facebook page for adult ADHD sufferers.
Lilly and Amylin teaming up to produce once-a-week diabetes pen.
Good stuff on Merck KGaA‘s oral MS drug. That company and Novartis both bringing groundbreaking new ones to market.
LATE BREAKING – big cuts at Seattle’s ZymoGenetics.
And, hey, why not a bit of speculation to spice up the day? Should Sanofi buy Biogen?
Finally, a bit of Training Fresh Air. I really like this approach by Daiichi-Sankyo.
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff